Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Martí Carvajal, Arturo J ^a   Cardona, Andrés Felipe ^b   Anand, Vidhu ^c   Solà, Ivan ^d  

^a School of Engineering Sciences and Industry   (Ecuador)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FEDRATINIB; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; MOMELOTINIB; PACRITINIB; PLACEBO; RUXOLITINIB; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ADVERSE EVENT; ANEMIA; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; META ANALYSIS; MYELOFIBROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLEEN SIZE; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 85041823831     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010298     Document Type: Article

References (80)

1. Bain BJ. The peripheral blood smear. In: Goldman L, Schafer AS editor(s). Goldman's Cecil Medicine. 24th Edition. Philadelphia, PA: Elsevier & Saunders, 2012:1024-31. [: ISBN 978-0-8089-2437-1]
2. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al.GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
3. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al.Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010;115(4):778-82. [PUBMED: 19965680]
4. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al.Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; Vol. 22, issue 2:437-8. [PUBMED: 17728787]
5. Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy 2011;12(10):1597-611. [PUBMED: 21457082]
6. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, et al.A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25(2):301-4. [PUBMED: 21052089]
7. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
8. Cases A. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs of Today 2003;39(7):477-95. [PUBMED: 12973399]
9. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al.New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113(13):2895-901. [PUBMED: 18988864]
10. Cervantes F, Pereira A. Advances in the understanding and management of primary myelofibrosis. Current Opinion in Oncology 2011;23(6):665-71. [PUBMED: 21892083]
11. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. http://ctu.dk/tsa/ (accessed 29 September 2011). Copenhagen: Central Trial Unit, 2011.
12. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. American Journal of Kidney Diseases 2001;38(2):415-25. [PUBMED: 11479173]
13. Food, Drug Administration. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf [accessed 22 March 2012].
14. Finazzi G, Xu M, Barbui T, Hoffman R. Essential thrombocythemia. In: Hoffman, Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1149-66. [: ISBN 978-0-443-06715-0]
15. Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands) 2012;17 Suppl 1:S129-32. [PUBMED: 22507800]
16. Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows 2008.
17. Greer JP, John Foerster, George M. Rodgers, Frixos Paraskevas, Bertil Glader, Daniel A. Arber Means RT. Wintrobe's Clinical Hematology. 12th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2009. [: ISBN 978-0-7817-6507-7]
18. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al.GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
19. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
20. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al.GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
21. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al.GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
22. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al.GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
23. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al.GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
24. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
25. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al.GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PUBMED: 21194891]
26. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2. [PUBMED: 21185693]
27. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al.GRADE guidelines 12. Preparing Summary of Findings tables - binary outcomes. Journal of Clinical Epidemiology 2012; Vol. May 18:Epub ahead of print. [PUBMED: 22609141]
28. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al.JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine 2012;366(9):787-98. [PUBMED: 22375970]
29. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
30. Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. Statistics in medicine 2011;30(9):903-21. [PUBMED: 21472757]
31. Hoffman R, Xu M, Barosi G. Primary myelofibrosis. In: Hoffman, Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125-47. [: ISBN 978-0-443-06715-0]
32. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. European Journal of Haematology 2009;82(5):329-38. [PUBMED: 19141119]
33. Lan GKK, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70(3):659-63.
34. Mesa R, Gale RP. Hypothesis: how do JAK2-inhibitors work in myelofibrosis. Leukemia Research 2009;33(9):1156-7. [PUBMED: 19450878]
35. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et al.The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research 2009;33(9):1199-203. [PUBMED: 19250674]
36. Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, et al.Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116(22):4436-8. [PUBMED: 20651074]
37. Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, et al.Phase1/-2 study of Pomalidomide in myelofibrosis. American Journal of Hematology 2010; Vol. 85, issue 2:129-30. [PUBMED: 20052748]
38. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, et al.Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011;117(21):4869-77. [PUBMED: 21480207]
39. Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nature Reviews. Drug Discovery 2012; Vol. 11, issue 2:103-4. [PUBMED: 22293561]
40. Mesa RA. The evolving treatment paradigm in myelofibrosis. Leukemia & Lymphoma 2012; Vol. Aug 14:Epub ahead of print. [PUBMED: 22793267]
41. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12. [PUBMED: 19631508]
42. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795-801. [PUBMED: 15148066]
43. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis. Drugs of Today 2011;47(11):817-27. [PUBMED: 22146225]
44. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncology 2011;7(9):1035-43. [PUBMED: 21919691]
45. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management 2012;8:95-103. [PUBMED: 22399854]
46. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011;25(2):218-25. [PUBMED: 21079613]
47. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Current Opinion in Hematology 2011;18(2):105-10. [PUBMED: 21245760]
48. Pardanani A. Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Leukemia 2012;Jan 30:Epub ahead of print. [DOI: 10.1038/leu.2012.21.; PUBMED: 22285996]
49. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [PUBMED: 9921604]
50. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al.A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115(9):1703-8. [PUBMED: 20008785]
51. Passamonti F, Maffioli M, Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Current Opinion in Hematology 2012;19(2):117-23. [PUBMED: 22227528]
52. Pastore A, Temussi PA. The two faces of Janus: functional interactions and protein aggregation. Current Opinion in Structural Biology 2012;22(1):30-7. [PUBMED: 22155180]
53. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18(6):580-93; discussion 661-6. [PUBMED: 9408720]
54. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998;351(9095):47-52. [PUBMED: 9433436]
55. Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, et al.Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. Journal of Clinical Oncology 2009;27(28):4760-6. [PUBMED: 19720904]
56. Qureshi M, Harrison C. Management of myelofibrosis - where next?. Expert Opinion on Pharmacotherapy 2011; Vol. 12, issue 10:1453-5. [PUBMED: 21651445]
57. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S. Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. Journal of Hematology & Oncology 2012;5(1):43. [PUBMED: 22852872]
58. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
59. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochemical Pharmacology 2012;83(9):1136-45. [PUBMED: 22209716]
60. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and present. Journal of Endocrinological Investigation 2009;32(8):704-16. [PUBMED: 19494706]
61. Stein BL, Crispino JD, Moliterno AR. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Current Opinion in Oncology 2011;23(6):609-16. [PUBMED: 21993415]
62. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al.Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002. [PUBMED: 21784880]
63. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, et al.Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of Clinical Oncology 2009;27(27):4563-9. [PUBMED: 19652059]
64. Tefferi A. How I treat myelofibrosis. Blood 2011;117(13):3494-504. [PUBMED: 21200024]
65. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology 2011;86(12):1017-26. [PUBMED: 22086865]
66. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. The New England Journal of Medicine 2011; Vol. 365, issue 15:1455-7. [PUBMED: 21995409]
67. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clinic proceedings. Mayo Clinic 2011;86(12):1188-91. [PUBMED: 22034658]
68. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Reviews 2011;25(5):229-37. [PUBMED: 21742423]
69. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012;119(12):2721-30. [PUBMED: 22279053]
70. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90(8):1128-32. [PUBMED: 16079113]
71. Thiele J, Kvasnicka HM. Myelofibrosis - what's in a name? Consensus on definition and EUMNET grading. Pathobiology 2007;74(2):89-96. [PUBMED: 17587880]
72. Thompson JE. JAK protein kinase inhibitors. Drug News & Perspectives 2005;18(5):305-10. [PUBMED: 16193102]
73. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38(1):276-86. [PUBMED: 18824467]
74. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). 2011. http://ctu.dk/tsa/files/tsa_manual.pdf 2011 (Accessed 30 April 2012).
75. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;5:16. [PUBMED: 17555582]
76. Vannucchi AM. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis. Leukemia Research 2009;33(12):1581-3. [PUBMED: 19573914]
77. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al.Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. The New England Journal of Medicine 2010;363(12):1117-27. [PUBMED: 20843246]
78. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine 2012;366(9):799-807. [PUBMED: 22375971]
79. Wen Q, Goldenson B, Crispino JD. Normal and malignant megakaryopoiesis. Expert Reviews in Molecular Medicine 2011;13:e32. [PUBMED: 22018018]
80. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]